Pharma bankruptcy
Dendreon appoints new R&D lead
Dr Bruce Brown joins the Californian biopharmaceutical group as senior VP
Valeant uncouples Dendreon and skincare brands to cut debt
Agrees deals worth $2.1bn with L’Oreal and Sanpower Group
NewLink pancreatic cancer vaccine flunks phase III test
Survival rate slightly lower for patients on vaccine than those in control group
Dendreon wins IQWiG U-turn for its immunotherapy Provenge
New data for its troubled cancer drug convinces German HTA body of its added benefit
Good NICE news for Pfizer, but Dendreon drug rejected
Kidney cancer drug Inlyta backed but prostate cancer treatment Provenge is not
Valeant and Shire said to be evaluating potential Salix bids
Valeant currently in final stages of Provenge acquisition
Valeant lead bidder for troubled Dendreon
Willing to pay $296m for company behind prostate cancer vaccine Provenge
NICE says cost of Dendreon’s cancer vaccine is too high
Another blow as the bankrupt company goes to auction next month
Dendreon to go to auction without initial bidder
A selection for a bidder wanting to pay the minimum price has not been made
Dendreon’s cancer vaccine wins EU approval
Provenge approved for use in prostate cancer three years after US recommendation
